Inhaled nitric oxide in premature infants: Effect on tracheal aspirate and plasma nitric oxide metabolites

M. A. Posencheg, A. J. Gow, W. E. Truog, R. A. Ballard, A. Cnaan, S. G. Golombek, P. L. Ballard

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective:Inhaled nitric oxide (iNO) is a potential new therapy for prevention of bronchopulmonary dysplasia and brain injury in premature infants. This study examined dose-related effects of iNO on NO metabolites as evidence of NO delivery.Study Design:A subset of 102 premature infants in the NO CLD trial, receiving 24 days of iNO (20 p.p.m. decreasing to 2 p.p.m.) or placebo, were analyzed. Tracheal aspirate (TA) and plasma samples collected at enrollment and at intervals during study gas were analyzed for NO metabolites.Result:iNO treatment increased NO metabolites in TA at 20 and 10 p.p.m. (1.7- to 2.3-fold vs control) and in plasma at 20, 10, and 5 p.p.m. (1.6- to 2.3-fold). In post hoc analysis, treated infants with lower metabolite levels at entry had an improved clinical outcome.Conclusion:iNO causes dose-related increases in NO metabolites in the circulation as well as lung fluid, as evidenced by TA analysis, showing NO delivery to these compartments.

Original languageEnglish
Pages (from-to)275-280
Number of pages6
JournalJournal of Perinatology
Volume30
Issue number4
DOIs
Publication statusPublished - Apr 2010
Externally publishedYes

Fingerprint

Premature Infants
Nitric Oxide
Bronchopulmonary Dysplasia
Brain Injuries
Gases
Placebos
Lung
Therapeutics

Keywords

  • Bronchopulmonary dysplasia
  • Nitrite
  • NO CLD trial

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Pediatrics, Perinatology, and Child Health

Cite this

Posencheg, M. A., Gow, A. J., Truog, W. E., Ballard, R. A., Cnaan, A., Golombek, S. G., & Ballard, P. L. (2010). Inhaled nitric oxide in premature infants: Effect on tracheal aspirate and plasma nitric oxide metabolites. Journal of Perinatology, 30(4), 275-280. https://doi.org/10.1038/jp.2009.155

Inhaled nitric oxide in premature infants : Effect on tracheal aspirate and plasma nitric oxide metabolites. / Posencheg, M. A.; Gow, A. J.; Truog, W. E.; Ballard, R. A.; Cnaan, A.; Golombek, S. G.; Ballard, P. L.

In: Journal of Perinatology, Vol. 30, No. 4, 04.2010, p. 275-280.

Research output: Contribution to journalArticle

Posencheg, MA, Gow, AJ, Truog, WE, Ballard, RA, Cnaan, A, Golombek, SG & Ballard, PL 2010, 'Inhaled nitric oxide in premature infants: Effect on tracheal aspirate and plasma nitric oxide metabolites', Journal of Perinatology, vol. 30, no. 4, pp. 275-280. https://doi.org/10.1038/jp.2009.155
Posencheg, M. A. ; Gow, A. J. ; Truog, W. E. ; Ballard, R. A. ; Cnaan, A. ; Golombek, S. G. ; Ballard, P. L. / Inhaled nitric oxide in premature infants : Effect on tracheal aspirate and plasma nitric oxide metabolites. In: Journal of Perinatology. 2010 ; Vol. 30, No. 4. pp. 275-280.
@article{7e5d3a641ceb4c95ab0b3c0643c7cc67,
title = "Inhaled nitric oxide in premature infants: Effect on tracheal aspirate and plasma nitric oxide metabolites",
abstract = "Objective:Inhaled nitric oxide (iNO) is a potential new therapy for prevention of bronchopulmonary dysplasia and brain injury in premature infants. This study examined dose-related effects of iNO on NO metabolites as evidence of NO delivery.Study Design:A subset of 102 premature infants in the NO CLD trial, receiving 24 days of iNO (20 p.p.m. decreasing to 2 p.p.m.) or placebo, were analyzed. Tracheal aspirate (TA) and plasma samples collected at enrollment and at intervals during study gas were analyzed for NO metabolites.Result:iNO treatment increased NO metabolites in TA at 20 and 10 p.p.m. (1.7- to 2.3-fold vs control) and in plasma at 20, 10, and 5 p.p.m. (1.6- to 2.3-fold). In post hoc analysis, treated infants with lower metabolite levels at entry had an improved clinical outcome.Conclusion:iNO causes dose-related increases in NO metabolites in the circulation as well as lung fluid, as evidenced by TA analysis, showing NO delivery to these compartments.",
keywords = "Bronchopulmonary dysplasia, Nitrite, NO CLD trial",
author = "Posencheg, {M. A.} and Gow, {A. J.} and Truog, {W. E.} and Ballard, {R. A.} and A. Cnaan and Golombek, {S. G.} and Ballard, {P. L.}",
year = "2010",
month = "4",
doi = "10.1038/jp.2009.155",
language = "English",
volume = "30",
pages = "275--280",
journal = "Journal of Perinatology",
issn = "0743-8346",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Inhaled nitric oxide in premature infants

T2 - Effect on tracheal aspirate and plasma nitric oxide metabolites

AU - Posencheg, M. A.

AU - Gow, A. J.

AU - Truog, W. E.

AU - Ballard, R. A.

AU - Cnaan, A.

AU - Golombek, S. G.

AU - Ballard, P. L.

PY - 2010/4

Y1 - 2010/4

N2 - Objective:Inhaled nitric oxide (iNO) is a potential new therapy for prevention of bronchopulmonary dysplasia and brain injury in premature infants. This study examined dose-related effects of iNO on NO metabolites as evidence of NO delivery.Study Design:A subset of 102 premature infants in the NO CLD trial, receiving 24 days of iNO (20 p.p.m. decreasing to 2 p.p.m.) or placebo, were analyzed. Tracheal aspirate (TA) and plasma samples collected at enrollment and at intervals during study gas were analyzed for NO metabolites.Result:iNO treatment increased NO metabolites in TA at 20 and 10 p.p.m. (1.7- to 2.3-fold vs control) and in plasma at 20, 10, and 5 p.p.m. (1.6- to 2.3-fold). In post hoc analysis, treated infants with lower metabolite levels at entry had an improved clinical outcome.Conclusion:iNO causes dose-related increases in NO metabolites in the circulation as well as lung fluid, as evidenced by TA analysis, showing NO delivery to these compartments.

AB - Objective:Inhaled nitric oxide (iNO) is a potential new therapy for prevention of bronchopulmonary dysplasia and brain injury in premature infants. This study examined dose-related effects of iNO on NO metabolites as evidence of NO delivery.Study Design:A subset of 102 premature infants in the NO CLD trial, receiving 24 days of iNO (20 p.p.m. decreasing to 2 p.p.m.) or placebo, were analyzed. Tracheal aspirate (TA) and plasma samples collected at enrollment and at intervals during study gas were analyzed for NO metabolites.Result:iNO treatment increased NO metabolites in TA at 20 and 10 p.p.m. (1.7- to 2.3-fold vs control) and in plasma at 20, 10, and 5 p.p.m. (1.6- to 2.3-fold). In post hoc analysis, treated infants with lower metabolite levels at entry had an improved clinical outcome.Conclusion:iNO causes dose-related increases in NO metabolites in the circulation as well as lung fluid, as evidenced by TA analysis, showing NO delivery to these compartments.

KW - Bronchopulmonary dysplasia

KW - Nitrite

KW - NO CLD trial

UR - http://www.scopus.com/inward/record.url?scp=77950517036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950517036&partnerID=8YFLogxK

U2 - 10.1038/jp.2009.155

DO - 10.1038/jp.2009.155

M3 - Article

C2 - 19812581

AN - SCOPUS:77950517036

VL - 30

SP - 275

EP - 280

JO - Journal of Perinatology

JF - Journal of Perinatology

SN - 0743-8346

IS - 4

ER -